Germany Biosimilars Market Analysis

Germany Biosimilars Market Analysis

$ 3999

Germany's biosimilar market size was valued at $0.7 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.4% from 2022 to 2030 and will reach $3.1 Bn in 2030. The market is segmented by product type and indication type. The German biosimilar market will grow with the rising prevalence of chronic diseases in Germany, including cancer, diabetes, and autoimmune disorders. The key market players are Sandoz GmbH (AUT), Fresenius Kabi Deutschland GmbH (DEU), Hexal AG (DEU), STADA Arzneimittel AG (DEU), Sanofi-Aventis Deutschland GmbH (FRA), Teva GmbH (ISR), and others.

ID: IN10DEPH027 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Chandani Patel

Buy Now

Germany Biosimilars Market Executive Summary

Germany's biosimilars market size was valued at $0.7 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.4% from 2022 to 2030 and will reach $3.1 Bn in 2030. Since 2006, biosimilars have been accessible in Germany, where they have one of the largest markets on the continent. Biosimilars are biological drugs that are extremely similar to a reference drug, a biological drug that has already received approval. They are designed to be equally safe and effective as the reference drug. The European Medicines Agency (EMA), which establishes standards for their research and approval, oversees the approval of biosimilars in Germany. With additional criteria to prove comparability with the reference biologic, the approval procedure for biosimilars in Germany is identical to that for biologics.

The cost reductions that biosimilars provide in comparison to reference biologics are one of the major factors driving the market for them in Germany. Biosimilars are an appealing choice for healthcare payers looking to save costs since they are often less expensive than the reference biologics they are based on. The emergence of biosimilars has additionally aided in boosting market competition for biologics, which may result in cheaper costs for patients. It is anticipated that the German biosimilar business would expand as additional biologics lose their patent protection and as physician and patient knowledge rise.

germany biosimilars market analysis

Market Dynamics

Market Growth Drivers

The demand for biosimilars is being driven by the rising prevalence of chronic diseases in Germany, including cancer, diabetes, and autoimmune disorders. Because they are less expensive than biologics, biosimilars are a desirable choice for patients, doctors, and healthcare payers looking for affordable medicines.

Biosimilars are now available on the market as a result of the patents on numerous biologics in Germany expiring. The use of biosimilars to lower healthcare costs has been aggressively encouraged by the German government, which has contributed to the expansion of the biosimilar industry.

Market Restraints

Despite the advantages of biosimilars, their use is resisted by doctors and patients due to a lack of knowledge regarding their safety and effectiveness. Costly Development: Research and development expenditures are high when creating a biosimilar, which might be prohibitive for small and medium-sized businesses.

Additionally, the production of biosimilars requires a sophisticated manufacturing process, and it can be difficult for firms to prove that their medicines are substantially comparable to the reference biologic.

Competitive Landscape

Key Players

  • Sandoz GmbH (AUT)
  • Fresenius Kabi Deutschland GmbH (DEU)
  • Hexal AG (DEU)
  • STADA Arzneimittel AG (DEU)
  • Sanofi-Aventis Deutschland GmbH (FRA)
  • Teva GmbH (ISR)
  • Pfizer Deutschland GmbH (USA)
  • Mylan Healthcare GmbH (USA)
  • Biogen GmbH (USA)
  • Amgen GmbH (USA)

Healthcare Policies and Regulatory Landscape

The European Medicines Agency (EMA) is in charge of biosimilar regulations in Germany, which are identical to those that apply to reference biologics. Biosimilars must, according to the EMA, show that they are comparable to the reference biologic in terms of quality, safety, and effectiveness. To prove their resemblance to the reference biologic, biosimilars must go through a rigorous clinical development program that includes comparison studies. Because part of the data may be inferred from the reference biologic, the approval procedure for biosimilars in Germany is often quicker than that for reference biologics. Due to the intricacy of the manufacturing process and the requirement to show comparability, the approval procedure might yet take many years.

The G-BA (Gemeinsamer Bundesausschuss), the joint committee of the Federal Joint Committee (G-BA), oversees reimbursement for biosimilars in Germany. The G-BA is in charge of deciding whether medical goods and services are reimbursed in Germany. The same regulations governing reference biologic reimbursement apply to biosimilars, and their reimbursement rate is determined by the cost of the reference biologic. To lower healthcare costs, the German healthcare system has been actively encouraging the use of biosimilars. In addition to being less expensive than reference biologics, biosimilars also face price rivalry from other producers, which may result in additional price drops.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company Overview Product Applications and Services Recent Developments Partnerships Ecosystem Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Germany Biosimilars Market Segmentation

By Product

The monoclonal antibodies, insulin, granulocyte colony-stimulating factor, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, enoxaparin sodium, glucagon, and calcitonin are among the product categories that make up the biosimilars market. Monoclonal antibodies held a sizable portion of the market in 2020. The market is being driven by elements including the widespread use of monoclonal antibodies in the treatment of autoimmune diseases, cancer, and osteoporosis, as well as the affordability of such treatments.

  • Monoclonal Antibodies
    • Infliximab
    • Trastuzumab
    • Rituximab
    • Adalimumab
    • Other monoclonal antibodies (bevacizumab, cetuximab, ranibizumab, denosumab, and eculizumab)
  • Insulin
  • Granulocyte Colony-Stimulating Factor
  • Erythropoietin
  • Recombinant Human Growth Hormone
  • Etanercept
  • Follitropin
  • Teriparatide
  • Interferons
  • Enoxaparin Sodium
  • Glucagon
  • Calcitonin

By Indication

The biosimilars market is divided into oncology, autoimmune and inflammatory diseases, chronic illnesses, blood disorders, growth hormone insufficiency, infectious diseases, and other indications based on the indication (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). The market's largest sector in 2020 will be oncology. This market is expanding as a result of elements like the reduced cost of biosimilars compared to novel biologics and the increased incidence and prevalence of cancer.

  • Oncology
  • Inflammatory & Autoimmune Disorders
  • Chronic Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Indications (infertility, hypoglycemia, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases)

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.


Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:



Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.



Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 08 December 2023
Updated by: Dhruv Joshi

Related reports (by category)

Related reports (by geography)

subscribe to our newsletter